Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-intensified TICE in refractory or relapsed poor-prognosis germ cell tumors
2008-005068-14Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Mar 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide, carboplatin and etoposide in germ cell tumor (GCT) and refractory germ cell tumor (RGCT), sponsored by Institut Claudius Regaud. Primary endpoints: Complete response rate and Pathologic complete response rate. Started Mar 2009; status: completed.
02
Drugs
paclitaxelifosfamidecarboplatinetoposide
03
Conditions
germ cell tumor (GCT)refractory germ cell tumor (RGCT)
Beyond the preview
Go deeper on 2008-005068-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005068-14.